Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | HRH2 | P25021 | 5/20 | 0.43 |
| ▸ | HRH1 | P35367 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1618052 | 0.91 | KCNH2 (0.48) | KCNH2HRH3HRH2HRH1KDM4E | |
| SCHEMBL1619268 | 0.90 | KCNH2 (0.51) | KCNH2HRH3HRH2HRH1MEN1 | |
| SCHEMBL1619372 | 0.89 | HTR1A (0.39) | KCNH2HRH2HRH1KDM4EALDH1A1 | |
| SCHEMBL1619282 | 0.88 | CHRM3 (0.38) | KCNH2HRH3HRH2HRH1KDM4E | |
| SCHEMBL4507239 | 0.86 | KCNH2 (0.43) | KCNH2HRH3HRH2HRH1ALDH1A1 | |
| SCHEMBL5013138 | 0.86 | MMP2 (0.41) | KCNH2HRH3HRH2HRH1ALDH1A1 | |
| SCHEMBL1619343 | 0.84 | KCNH2 (0.62) | KCNH2KDM4EALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL1619412 | 0.83 | KCNH2 (0.50) | KCNH2HRH3HRH2HRH1KDM4E | |
| SCHEMBL1619080 | 0.82 | KCNH2 (0.43) | KCNH2HRH3HRH1 | |
| SCHEMBL1619417 | 0.82 | DPP4 (0.41) | KCNH2ALDH1A1MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928225-B2 | Oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2011-04-19 | — | — | US | claimed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-7928225-B2 | Oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2011-04-19 | — | — | US | disclosed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 6/4885HRH3 448/4885HRH2 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.